Please use this identifier to cite or link to this item:
|Title:||Drug discovery prospect from untapped species: Indications from approved natural product drugs||Authors:||Zhu, F.
|Issue Date:||11-Jul-2012||Citation:||Zhu, F., Ma, X.H., Qin, C., Tao, L., Liu, X., Shi, Z., Zhang, C.L., Tan, C.Y., Chen, Y.Z., Jiang, Y.Y. (2012-07-11). Drug discovery prospect from untapped species: Indications from approved natural product drugs. PLoS ONE 7 (7) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0039782||Abstract:||Due to extensive bioprospecting efforts of the past and technology factors, there have been questions about drug discovery prospect from untapped species. We analyzed recent trends of approved drugs derived from previously untapped species, which show no sign of untapped drug-productive species being near extinction and suggest high probability of deriving new drugs from new species in existing drug-productive species families and clusters. Case histories of recently approved drugs reveal useful strategies for deriving new drugs from the scaffolds and pharmacophores of the natural product leads of these untapped species. New technologies such as cryptic gene-cluster exploration may generate novel natural products with highly anticipated potential impact on drug discovery. © 2012 Zhu et al.||Source Title:||PLoS ONE||URI:||http://scholarbank.nus.edu.sg/handle/10635/105852||ISSN:||19326203||DOI:||10.1371/journal.pone.0039782|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|2012_Drug_discovery_prospect_from_untapped-published.PDF||565.43 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.